非编码RNA及其在癌症治疗相关心脏毒性中的潜在利用
Riccardo Bernasconi1, Gabriela M Kuster1,2
1Myocardial Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland.
British journal of pharmacology
|May 27, 2024
概括
癌症幸存者面临来自治疗的心血管风险增加. 非编码RNAs (ncRNAs) 在这种心脏毒性中发挥作用,并可能提供未来的心脏保护策略.
科学领域:
- 心血管生物学 心血管生物学
- 分子瘤学分子瘤学
- 在RNA治疗方面,RNA疗法.
背景情况:
- 由于治疗的进步,癌症的生存率正在增加.
- 癌症幸存者患心血管疾病的发病率更高.
- 与癌症治疗相关的心血管毒性是一个重大的临床挑战.
研究的目的:
- 审查癌症治疗相关心脏毒性的关键特征.
- 要总结非编码RNAs (ncRNAs) 在心脏毒性的已知作用.
- 探索ncRNAs作为心脏保护治疗点的潜力.
主要方法:
- 关于ncRNAs和心脏毒性的当前研究的文献综述.
- 对ncRNA参与与心血管健康和癌症治疗相关的生物过程的分析.
- 综合证据,将ncRNA与癌症治疗相关心脏毒性联系起来.
主要成果:
- 非编码RNAs (ncRNAs),包括microRNAs,长ncRNAs和圆形RNAs,调节基因表达和细胞功能.
- ncRNAs与心血管疾病和癌症的发展有关.
- 新出现的证据强调了ncRNAs在癌症治疗相关心脏毒性中的作用.
结论:
- ncRNAs是细胞过程和疾病发展的关键调节者.
- 了解ncRNAs在心脏毒性中的作用对于管理癌症幸存者的健康至关重要.
- ncRNAs代表了有希望的治疗点,用于预防或治疗癌症治疗的心血管并发症.
相关概念视频
lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
Experimental RNAi
6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Types of RNA
5.7K
Three main types of RNA are involved in protein synthesis: messenger RNA (mRNA), transfer RNA (tRNA), and ribosomal RNA (rRNA). These RNAs perform diverse functions and can be broadly classified as protein-coding or non-coding RNA. Non-coding RNAs play important roles in regulating gene expression in response to developmental and environmental changes. Non-coding RNAs in prokaryotes can be manipulated to develop more effective antibacterial drugs for human or animal use.
RNA Performs Diverse...
RNA Performs Diverse...
5.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K


